<DOC>
	<DOCNO>NCT03033368</DOCNO>
	<brief_summary>To describe immunologic virologic outcome ( HIV RNA , CD4 ) follow switch EFV RPV virologically suppress adolescent</brief_summary>
	<brief_title>Rilpivirine Virologically Suppressed Adolescents</brief_title>
	<detailed_description>Study Procedures : At screen , informed consent process provide participant , participant legally acceptable representative study procedure . Only adolescent know HIV status ask give assent . Twenty adolescent follow HIV-NAT Department Pediatrics , Faculty Medicine , Chulalongkorn University ask participate PK sub study . Participant enrol PK substudy ask take RPV morning breakfast commence PK evaluation witness dose . After PK study week 4 , Participant follow 80 adolescent end study . Participant ask provide small hair sample RPV concentration week 4 , 12 , 24 , 48 switching . This option therefore participant refuse provide hair sample visit . HIV RNA level perform baseline , week 12 , 24 48 visit . If HIV-RNA visit &gt; 50 copies/ml , HIV-RNA test repeat within 4-8 week adherence improvement counseling . At visit , HIV-RNA â‰¥1000 copies/ml , genotypic resistance test perform . Modification treatment resistance safety consideration subject site principal investigator 's decision .</detailed_description>
	<mesh_term>Rilpivirine</mesh_term>
	<criteria>HIVinfected adolescent age 1218 year ; Body weight &gt; 25 kilogram ; Currently treat stable EFVbased HAART ( EFV plus two nucleoside nucleotide reverse transcriptase inhibitor [ N ( ) RTI ] ) &gt; 3 month prior enrollment ; Plasma HIV RNA &lt; 50 copies/ml within last 12 month ; ALT &lt; 200 IU/L within last 12 month ; Caregivers give write informed consent adolescent know HIV status ( i.e. , fully disclose ) give assent Has evidence NNRTIassociated resistance mutation ( ) previous genotypic resistance test ; Currently PI ( ) HAART regimen ; Has currently active HIVrelated infection ( ) , ( The subject enrol infection control ) ; Has significant medical problem ( ) would compromise study result ( site principal investigator 's opinion ) ; Pregnancy ( postpartum woman allow ) ; Concomitant treatment drug know effect PK RPV ( carbamazepine , phenobarbital , phenytoin , rifampicin , rifabutin , omeprazole , esomeprazole , lansoprazole , erythromycin , clarithromycin , azithromycin , roxithromycin )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>immunological outcome</keyword>
	<keyword>virologic outcome</keyword>
	<keyword>HIV-1 infect adolescent</keyword>
	<keyword>EFV switch RPV</keyword>
	<keyword>Rilpivirine pharmacokinetic</keyword>
	<keyword>neuropsychiatric adverse event</keyword>
</DOC>